Bone marrow transplantation in multiple myeloma

Current Opinion in Oncology

Volumn 11, Issue 2, 1999, Pages 102-108

  Schlossman, Robert L ^a   Anderson, Kenneth C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; MELPHALAN; PREDNISONE; VINCRISTINE;

ALLOTRANSPLANTATION; AUTOGRAFT; BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CANCER SURVIVAL; DRUG CYTOTOXICITY; DRUG MEGADOSE; DRUG TOLERABILITY; HUMAN; MULTIMODALITY CANCER THERAPY; MULTIPLE MYELOMA; PRIORITY JOURNAL; REVIEW; TUMOR CELL; TUMOR IMMUNITY; WHOLE BODY RADIATION;

BONE MARROW TRANSPLANTATION; HUMANS; MULTIPLE MYELOMA; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0033060871     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199903000-00005     Document Type: Review

References (59)

1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1998. CA Cancer J Clin 1996, 48:10-11.
2. Oken MM, Harrington DP, Abramson N, Kyle RA, Knopse W, Glick JH: Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma-Results of Eastern Cooperative Oncology Group Study E2479. Cancer 1997, 79:1561-1567.
3. Ludwig H, Cohen AM, Polliack A, Huber H, Nachbaur A, Senn HJ, et al: Interferon-alpha for induction and maintenance in multiple myeloma: Results of two multicenter randomized trials and summary of other studies. Ann Oncol 1995, 6:467-476.
4. Kyle RA: Multiple myeloma: review of 869 cases. Mayo Clin Proc 1975, 50:29-40.
5. Kovacsovics TJ, Delaly A: Intensive treatment strategies in multiple myeloma. Semin Hematol 1997, 34:49-60. This article is a comprehensive review of the outcome of high-dose therapy in MM.
6. Harousseau J-L, Attal M: The role of autologous hematopoietic stem cell transplantation in multiple myeloma. Semin Hematol 1997, 34:61-66. The authors present a thorough analysis of the results of high-dose therapy and autografting in MM.
7. Bensinger WI, Demirer T, Buckner CD, Appelbaum FR, Storb R, Lilleby K, et al.: Syngeneic marrow transplantation in patients with multiple myeloma. Bone Marrow Transplant 1996, 18:527-531.
8. Bjorkstrand B, Ljungman P, Svensson H, Hermans J, Alegre A, Apperley J, et al.: Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A restrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996, 88:4711-4718.
9. Bensinger WI, Buchner CD, Anasetti C, Cliff R, Storb R, Barnett T, et al.: Allogeneic marrow transplantation for multiple myeloma: An analysis of risk factors on outcome. Blood 1996, 88:2787-2793.
10. Mehta J, Tricot G, Jagannath S, Ayers D,Singhal S, Siegel D, et al.: Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft. Bone Marrow Transplant 1998, 21:887-892.
11. Russell NH, Miflin G, Stainer C, McQuaker JG, Bienz N, Haynes AP, et al.: Allogeneic bone marrow transplant for multiple myeloma. Blood 1997, 89:2610-2611.
12. Ronconi S, Rosti G, Zamagni E, Lemoli RM, Bonini A, Belardinelli A, et al.: High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma. Bone Marrow Transplant 1998, 22:27-32.
13. Cavo M, Bandini G, Benni M, Gozzetti A, Ronconi S, Rosti G, et al.: High dose busuffan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma. Bone Marrow Transplant 1998, 22:27-32.
14. Anderson KC, Kyle RA, Berenson J: Multiple myeloma. In: Hematology 1997. Edited by Mc Arthur JR, Schecter GP, Platt OS. Washington, DC: American Society of Hematology; 1997:177-188.
15. Lee SJ, Weller EA, Alyea EP, Ritz J, Soiffer RJ: Efficacy and costs of granulocyte colony-stimulating factor in allogeneic T cell depleted bone marrow transplantation. Blood 1998, 92:2725-2729.
16. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B: Graft-versus myeloma effect: proof of principle. Blood 1996, 87:1196-1198.
17. Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen EJ: Graft-versus-myeloma effect in two cases. Lancet 1996, 347:800-801.
18. Lokhorst HM, Schattenberg JJ, Comelissen JJ, Thomas LLM, Verdonck LF: Donor lymphocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997, 90:4206-4211. The largest single center experience with DLI to treat relapse of MM post-allografting providing conclusive evidence of GVM.
19. Bertz H, Burger JA, Kunzmann R, Mertelsmann R, Finke J: Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation: evidence for a graft-versus-myeloma effect. Leukemia 1997, 11:281-283.
20. Alyea EP, Soiffer RJ, Canning C, Neuberg D, Schlossman R, Pickett C, et al.: Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998, 91:3671-3680.
21. Zomas A, Stefanoudaki K, Fisfis M, Papadaki T, Mehta J: Graft-versus-myeloma after donor leukocyte infusion-maintenance of marrow remission but extramedullary relapse with plasmacytomas. Bone Marrow Transplant 1998, 21:1163-1165.
22. Munshi NC, Govindarajan R, Drake R, Ding LM, Iyer R, Saylors R, et al.: Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional and are killed efficiently with ganciclovir. Blood 1997, 89:1334-1340.
23. Kwak LW, Pennington R, Longo DL: Active immunization of murine allogeneic bone marrow transplant donors with B-cell tumor-derived idiotype: A strategy for enhancing the specific antitumor effect of marrow grafts. Blood 1996, 87:3053-3060.
24. Kwak LW: Tumor vaccination strategies combined with autologous peripheral stem cell transplantation. Ann Oncol 1998, 9:S41-S46. This article reviews potential immunization strategies to enhance donor anti-MM immunity in allograft recipients.
25. Moreau P, Fiere D, Bezwoda WR, Facon T, Attal M, Laporte JP, et al.: Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalsn metphalan in patients with multiple myeloma. J Clin Oncol 1997, 15:660-666.
26. Bensinger WI, Rowley SD, Demirer T, Lilleby K, Clift RA, Appelbaum FR, et al.: High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. J Clin Oncoll 1996, 14:1447-1456.
27. Raje N, Powles R, Horton C, Millar B, Shepherd V, Middleton G, et al.: Comparison of marrow vs blood-derived stem cells for autografting in previously untreated multiple myeloma. Br J Cancer 1997, 75:1684-1689.
28. Desikan KR, Barlogie B, Jagannath S, Vesole DH, Siegel D, Fassas A, et al.: Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol 1998, 16:1547-1553.
29. Desikan KR, Jagannath S, Siegel D, Nelson J, Bracy D, Barlogie B, et al.: Collection of more hematopoietic progenitor cells with large volume leukapheresis in patients with multiple myeloma. Leuk Lymphoma 1998, 28:501-508.
30. Omede P, Tarella C, Palumbo A, Argentino C, Caracciolo D, Corradini P, et al.: Multiple myeloma: reduced plasma cell contamination in peripheral blood progenitor cell collections performed after repeated high-dose chemotherapy courses. Br J Haematol 1997, 99:685-691.
31. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al.: Autologous bone marrow transplantation versus conventional chemotherapy in multiple myeloma: a prospective, randomized trial. N Engl J Med 1996, 335:91-97.
32. Attal M, Payen C, Facon T, Michaux JL, Guilhot F, Moconduit M, et al.: Single versus double transplant in myeloma: a randomized trial of the Inter Groupe Francais du Myelome (IFM) [abstract]. Blood 1997, 90(Suppl):418a. An ongoing trial comparing single versus double high-dose therapy and autografting in MM.
33. Alegre A, Diaz-Mediavilla J, San-Miguel J, Martinez R, Garcia Larana J, Escudero A, et al.: Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM (Grupo Espanol de Trasplante Hematopoyetico-GETH) and PETHEMA. Bone Marrow Transplant 1998, 21:133-140.
34. Barlogie B, Jagannath S, Naucke S, Mattox S, Bracy D, Crowley J, et al.: Long-term follow-up after high-dose therapy for high-risk multiple myeloma. Bone Marrow Transplant 1998, 11:1101-1107.
35. Blade J, San Miguel JF, Fontanillas M, Alcala A, Maldonado J, GarciaConde J, et al.: Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/autotransplantation and who were conventionally treated. J Clin Oncol 1996, 14:2167-2173.
36. Billadeau D, Prosper F, Verfaillie C, Weisdorf D, Van Ness B: Sequential analysis of bone marrow and peripheral blood after stem cell transplant for myeloma shows disparate tumor involvement. Leukemia 1997, 11:1565-1570.
37. Zent CS, Wilson CS, Tricot G, Jagannath S, Siegel D, Desikan KR, et al.: Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood 1998, 91:3518-3523.
38. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S, et al.: Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997, 89:789-793.
39. Weaver CH, Zhen B, Schwartzberg LS, Leff R, Magee M, Geier L, et al.: Phase I-II evaluation of rapid sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myeloma. Bone Marrow Transplant 1998, 22:245-251.
40. Lemoli RM, Fortuna A, Motta MR, Rizzi S, Giudice V, Nannetti A, et al.: Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. Blood 1996, 87:1625-1634.
41. Kimlinger T, Witzig TE: Expression of the hematopoietic stem cell antigen CD34 on blood and bone marrow monoclonal plasma cells from patients with multiple myeloma. Bone Marrow Transplant 1997, 19:553-556.
42. Cremer FW, Kiel K, Sucker C, Wacker J, Atzberger A, Haas R, et al.: A rationale for positive selection of peripheral blood stem cells in multiple myeloma-highly purified CD34(+) cell fractions of leukapheresis products do not contain malignant cells. Leukemia 1997, 11:S41-S46.
43. Ventura MA, Martinelli G, Gozzetti A, Leopardi G, Ratta M, Cavo M, et al.: Selection and transplantation of autologous hematopoietic CD34+ cells for patients with multiple myeloma. Leuk Lymphoma 1997, 26:1-11.
44. Schiller G, Vescio R, Freytes C, Spitzer G, Lee M, Wu CH, et al.: Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma. Bone Marrow Transplant 1998, 21:141-145.
45. Vescio R, Schiller G, Stewart K, Ballester O, Noga S, Rugo H, et al.: Multicenter phase III trial to evaluate CD34+ selected vs. unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood 1999, in press.
46. Szczepek AJ, Bergsagel PL, Axelsson L, Brown CB, Belch AR, Pilarski LM: CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific igH VDJ gene rearrangements. Blood 1997, 89:1824-1833.
47. Tricot G, Gazitt Y, Leemhuis T, Jagannath S, Desikan KR, Siegel D, et al.: Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high-dose therapy in multiple myeloma. Blood 1998, 91:4489-4495.
48. Teoh G, Chen L, Urashima M, Tai YT, Celi LA, Chen D, et al.: Adenovirus vector based purging of multiple myeloma cells. Blood 1998, 92:4591-4601.
49. Treon SP, Mollick JA, Chauhan D, Urashima M, Teoh G, Ogata A, et al.: Muc-1 core protein glycoforms on multiple myeloma cells can be upregulated by dexamethasone. Blood 1999, in press.
50. Cunningham D, Powles R, Malpas J, Raje N, Milan S, Viner C, et al.: A randomized trial of maintenance interferon following a high-dose chemotherapy in multiple myeloma-long-term follow-up results. Br J Haematol 1998, 102:495-502.
51. Bergenbrant B, Yi Q, Osterborg A, Bjorkholm B, Osby E, Mellstedt H, et al.: Modulation of antiidiotyplc immune response by immunization with the autologous M component protein multiple myeloma patients. Br J Haematol 1996; 92:840-846.
52. Osterborg A, Yi Q, Henriksson L, Fagerberg J, Bergenbrant S, Jeddi-Tehrani M, et al.: Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8 and CD4 specific T cell responses. Blood 1998, 91:2459-2466.
53. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, et al.: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996, 2:52-58.
54. Gong J, Chen D, Kufe D: Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997, 3:558-561. The authors present a vaccination strategy with fusions of tumor cells and dendritic cells to enhance immune response.
55. Gong J, Chen L, Chen D, Kashiwaba M, Manome Y, Tanaka T, Kufe D: Induction of antigen-specific antitumor immunity with adenoviral-transduced dendritic cells. Gene Ther 1997, 4:1023-1028.
56. Tarte K, Lu ZY, Fiol G, Legouffe E, Rossi JF, Klein B: Generation of virtually pure and potentially proliferating dendritic cells from non-CD34 apheresis cells from patients with multiple myeloma. Blood 1997, 90:3482-3495.
57. Tarte K, Olsen SJ, Lu ZY, Legouffe E, Rossi JF, Chang Y, et al.: Clinical grade functional dendritic cells from patients with multiple myeloma are not infected with Kaposi's Sarcoma-Associated Herpesvirus. Blood 1998, 91:1852-1858.
58. Giralt S, Weber D, Colome M, Dimopoulos M, Mehra R, Van Besien K, et al.: Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. J Clin Oncol 1997, 15:667-673.
59. Yi Q, Dabadghao S, Osterborg A, Bergenbrant S, Holm G: Myeloma bone marrow plasma cells: Evidence for their capacity as antigen-presenting cells. Blood 1997, 90:1960-1967.